APA (7th ed.) Citation

RY, Y., G, Z., DM, W., XC, P., SB, W., JS, F., . . . GH, D. (2024). Corrigendum to "DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice" [Pharmacol. Biochem. Beha. Volume 139, Part A, December 2015, Pages 15-26]. Pharmacology, biochemistry, and behavior, 239, 173758. https://doi.org/10.1016/j.pbb.2024.173758

Chicago Style (17th ed.) Citation

RY, Yang, et al. "Corrigendum to "DL0410 Can Reverse Cognitive Impairment, Synaptic Loss and Reduce Plaque Load in APP/PS1 Transgenic Mice" [Pharmacol. Biochem. Beha. Volume 139, Part A, December 2015, Pages 15-26]." Pharmacology, Biochemistry, and Behavior 239 (2024): 173758. https://doi.org/10.1016/j.pbb.2024.173758.

MLA (9th ed.) Citation

RY, Yang, et al. "Corrigendum to "DL0410 Can Reverse Cognitive Impairment, Synaptic Loss and Reduce Plaque Load in APP/PS1 Transgenic Mice" [Pharmacol. Biochem. Beha. Volume 139, Part A, December 2015, Pages 15-26]." Pharmacology, Biochemistry, and Behavior, vol. 239, 2024, p. 173758, https://doi.org/10.1016/j.pbb.2024.173758.